12th Apr 2017 13:30
Additional listing
12 April 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has issued and allotted 190,000 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 20 April 2017. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
The total number of shares in issue, following admission, will be 69,991,624. The Company holds no shares in Treasury.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer
| Tel: +44 (0)20 3457 6900 |
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Henry Fitzgerald-O'Connor/Emma Gabriel
| Tel: +44 (0)20 7523 8350 |
Peel Hunt LLP (Joint Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert
| Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Related Shares:
SLN.L